Drugs that contain Lisinopril

1. List of Qbrelis drug patents

QBRELIS Litigations
Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9616096 AZURITY Lisinopril formulations
Nov, 2035

(12 years from now)

US10039800 AZURITY Lisinopril formulations
Nov, 2035

(12 years from now)

US10406199 AZURITY Lisinopril formulations
Nov, 2035

(12 years from now)

US10265370 AZURITY Lisinopril formulations
Nov, 2035

(12 years from now)

US9463183 AZURITY Lisinopril formulations
Nov, 2035

(12 years from now)

US11179434 AZURITY Lisinopril formulations
Nov, 2035

(12 years from now)

US10940177 AZURITY Lisinopril formulations
Nov, 2035

(12 years from now)

US9814751 AZURITY Lisinopril formulations
Nov, 2035

(12 years from now)

Market Authorisation Date: 29 July, 2016

Treatment: Treatment of hypertension; Method of treating hypertension; Treatment of heart failure; Treatment of myocardial infarction; Reduction of mortality in acute myocardial infarction; Acute myocardial infarction; Method of treatment of heart failure

Dosage: SOLUTION;ORAL

How can I launch a generic of QBRELIS before it's patent expiration?
More Information on Dosage

QBRELIS family patents

12

United States

2

China

2

European Union

1

Korea, Republic of

1

Hong Kong

1

Canada

1

Spain

1

Japan

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic

Other things you might be interested in